Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials

Current Diabetes Reports

Volumn 8, Issue 1, 2008, Pages 71-77

  Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID DERIVATIVE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC DYSLIPIDEMIA; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; RISK REDUCTION; VASCULAR DISEASE; WEIGHT REDUCTION;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE;

EID: 40749094524     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0013-2     Document Type: Review

References (28)

1. Thom T, Haase N, Rosamond W, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.
2. Cowie CC, Rust KF, Byrd-Holt DD, et al.: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
4. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
5. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
6. Grundy SM: Does the metabolic syndrome exist? Diabetes Care 2006, 29:1689-1692; discussion 1693-1696.
7. Grundy SM: Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 2006, 8(Suppl 1):S21-S27.
8. Raynolds MV, Awald PD, Gordon DF, et al.: Lipoprotein lipase gene expression in rat adipocytes is regulated by isoproterenol and insulin through different mechanisms. Mol Endocrinol 1990, 4:1416-1422.
9. Superko HR: Small, dense, low-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2000, 2:226-231.
10. Nesto RW: Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005, 5:379-387.
11. Ginsberg HN: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006, 91:383-392.
12. Conde K, Pineda G, Newton RS, Fernandez ML: Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Biochem Pharmacol 1999, 58:1209-1219.
13. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
14. Qu S, Su D, Altomonte J, et al.: PPAR-(alpha) mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab 2007, 292:E421-E434.
15. Fruchart JC, Duriez P: Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barcelona) 2006, 42:39-64.
16. Superko RH: Lipoprotein subclasses and atherosclerosis. Front Biosci 2001, 6:D355-365.
17. Fruchart JC, Staels B, Duriez P: New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis. Bull Acad Natl Med 2001, 185:63-74; discussion 74-75.
18. Chang AM, Smith MJ, Galecki AT, et al.: Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab 2006, 91:3303-3309.
19. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
20. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
21. Arnett DK, Jacobs DR Jr, Luepker RV, et al.: Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 2005, 112:3884-3891.
22. Heart Protection Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
23. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. Engl J Med 1987, 317:1237-1245.
24. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341, 410-418.
25. Robins SJ, Rubins HB, Faas FH, et al.; Veterans Affairs HDL Intervention Trial (VA-HIT): Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003, 26, 1513-1517.
26. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
27. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med 2005, 353:2643-2653.
28. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.